Rituximab Not Noninferior to Ocrelizumab for Relapsing-Remitting MS

WEDNESDAY, June 14, 2023 -- For patients with relapsing-remitting multiple sclerosis (MS), rituximab is not noninferior to ocrelizumab, according to a study published online June 12 in JAMA Neurology. Izanne Roos, M.B.Ch.B., Ph.D., from Royal...

https://www.drugs.com/news/rituximab-not-noninferior-ocrelizumab-relapsing-remit...

Source: Drugs.com - Pharma News - June 14, 2023 Category: Pharmaceuticals Source Type: news